Description
Introduction:
Dasatinib, sold under the brand name Sprycel, is a targeted therapy medication used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Specifically it is used to treat cases that are Philadelphia chromosome-positive (Ph+). It is a tyrosine-kinase inhibitor and works by blocking a number of tyrosine kinases such as Bcr-Abl and the Src kinase family.
Intended Use:
The KRIBIOLISA Dasatinib ELISA kit is used for quantitative estimation of Dasatinib in human serum and plasma. The kit is for research use only and not for diagnostic use.
Principle:
The Dasatinib ELISA is a competitive inhibition immunoassay for the determination of Dasatinib. A varying concentration of unlabeled Dasatinib Standard or diluted Sample, constant concentration of ABL1 protein and biotin conjugated Anti-ABL1 are added and incubated to the microtitre plate coated with Anti-ABL1. Dasatinib inhibits the binding of Anti-ABL1 to ABL1 protein. Streptavidin:HRP conjugate is added and incubated. Upon washing, unbound Strep:HRP Conjugate will be removed. Bound Streptavidin:HRP conjugate complex will produce a soluble blue colored product after the addition of TMB Substrate. The enzyme reaction is stopped by dispensing of stop solution into the wells. The optical density (OD) of the solution at 450 nm is inversely proportional to the amount of bound Dasatinib present in the standards or samples.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!